EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria

Fikriye Kalkan, Sait Yeşillik, Fevzi Demirel, Ezgi Sönmez, Yasemin Balaban, Mustafa İlker İnan, Özgür Kartal

Anais Brasileiros de Dermatologia · 2025

DOI: 10.1016/j.abd.2024.02.006 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Anais Brasileiros de Dermatologia, 2025. Verfasst von Fikriye Kalkan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Allergy, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey. Electronic address: fikr…. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents, Cost-Benefit Analysis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsCost-Benefit AnalysisHumansFemaleMaleAdultTreatment OutcomeMiddle AgedSeverity of Illness IndexTime FactorsYoung AdultQuality of LifeFollow-Up Studies

Stichwörter der Autor:innen

Chronic urticariaOmalizumabSymptom assessment

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Department of Immunology and Allergy, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey. Electronic address: fikriyehandan@gmail.com.
  • Department of Immunology and Allergy, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.

Zitieren

APA

Kalkan, F., Yeşillik, S., Demirel, F., Sönmez, E., Balaban, Y., İnan, M. İ., & Kartal, Ö. (2025). Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria. Anais Brasileiros de Dermatologia. https://doi.org/10.1016/j.abd.2024.02.006

Vancouver

Kalkan F, Yeşillik S, Demirel F, Sönmez E, Balaban Y, İnan Mİ, et al. Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria. Anais Brasileiros de Dermatologia. 2025. doi:10.1016/j.abd.2024.02.006

BibTeX
@article{Kalkan2025,
  author = {Kalkan, Fikriye and Yeşillik, Sait and Demirel, Fevzi and Sönmez, Ezgi and Balaban, Yasemin and İnan, Mustafa İlker and Kartal, Özgür},
  title = {Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria},
  journal = {Anais Brasileiros de Dermatologia},
  year = {2025},
  doi = {10.1016/j.abd.2024.02.006}
}
Kostenlos starten →